Zanzalintinib in Unresectable and Progressive MPGGs

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT07714551
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Paraganglioma
  • Pheochromocytoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Zanzalintinib — DRUG
    Route: Oral Schedule: Daily

Study Details

This study is to examine the effects of oral daily zanzalintinib in participants with unresectable, progressive metastatic pheochromocytoma or paraganglioma.

Key Dates

First listed
Jul 20, 2026
Start date
Jan 9, 2027
Status verified
Jul 2026
Primary completion
Jan 1, 2031
Completion
Jan 1, 2032

Study Design

Enrollment
14 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Zanzalintinib
    Participants receive zanzalintinib orally once daily.

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: Assessed every 8 weeks during treatment. The estimated treatment duration is up to 16 months. ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Brigham and Women's Hospital (BWH)BostonMassachusetts02215
Kimberly Perez, MD
[email protected]
6176326491
Kimberly Perez, MD (PRINCIPAL_INVESTIGATOR)
Dana-Farber Cancer InstituteBostonMassachusetts02215
Kimberly Perez, MD
[email protected]
6176326491

Find similar trials in Boston, MA

By research site
Brigham and Women's Hospital (BWH)· Boston, MADana-Farber Cancer Institute· Boston, MA

Related Studies